卡培他濱與調強放療用于食管癌術后縱隔淋巴結轉移中的臨床效果

[摘要] 目的 探討卡培他濱與調強放療治療食管癌術后縱隔淋巴結轉移中的臨床效果。方法 方便選取2014年4月—2016年5月該院收治的食管癌術后縱隔淋巴結轉移患者60例為對象，分為對照組（n=29）采用單純強調化療，治療組（n=31）采用卡培他濱與調強放療，比對兩組療效。 結果 治療組緩解有效率為96.77%，對照組緩解有效率為65.52%；且治療組1年生存率90.63%和2年生存率58.06%均高于對照組1年生存率65.52%和2年生存率34.48%，兩組差異有統計學意義（P<0.05）。結論 卡培他濱與調強放療應用于食管癌術后縱隔淋巴結轉移中的治療效果顯著，有助于緩解患者病情，提高其生存率，安全性高，值得推廣。

[關鍵詞] 卡培他濱；調強放療；食管癌；淋巴結轉移

[中圖分類號] R735.1 [文獻標識碼] A [文章編號] 1674-0742（2016）12（c）-0097-03

[Abstract] Objective To explore the clinical effect of applying capecitabine and intensity modulated radiation therapy to treat mediastinal lymph node metastasis after esophageal cancer operation. Methods Convenient selection 60 patients with mediastinal lymph node metastasis after esophageal cancer operation treated in our hospital from April 2014 to May 2016 were selected as research objects， and were divided into two groups. The control group（n=29） only received intensity modulated radiation therapy， and the treatment group（n=31）was treated with capecitabine and intensity modulated radiation therapy. The efficacy of two groups was compared. Results The treatment group alleviate the effective rate was 96.77%， the control level effective rate was 65.52%； And the treatment group 1 year survival rate was 90.63% and 2 year survival rate was 58.06% higher than control group 1 year survival rate was 65.52% and 2 year survival rate was 34.48%， comparable to the two groups（P<0.05）. Conclusion Applying capecitabine and intensity modulated radiation therapy to treat mediastinal lymph node metastasis after esophageal cancer operation not only has evident treatment effect and helps to relieve the disease condition of patients， but also can improve the survival rate and is safe， which is worthy of promotion.

[Key words] Capecitabine； Intensity modulated radiation therapy；Esophageal cancer；Lymphatic metastasis

食管癌是臨床上常見的惡性腫瘤之一，近年來，食管癌疾病發病率居高不下，是我國病死率較高的疾病，嚴重影響了人們的身體健康。由于此疾病在早期不易發現，所以當大部分患者發現時已經進入了中晚期階段[1]。因此在治療食管癌術后縱隔淋巴結轉移中，需要對食管癌患者的治療加以重視，以致改善患者的病情，提高其生活質量。單純的調強化療效果較差，目前，卡培他濱與調強放療已成為治療中晚期食管癌的主要手段[2]。該研究通過方便選取2014年4月—2016年5月期間在該院接受治療的60例食管癌術后縱隔淋巴結轉移患者展開研究，給予對照組采用單純調強化療，治療組采用卡培他濱與調強放療，對兩組療效進行分析，期待能提升患者救治效果，現報道如下。……